Long-Term Effects of Inhaled Corticosteroids on FEV1 in Patients with Chronic Obstructive Pulmonary Disease
- 17 June 2003
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 138 (12) , 969-973
- https://doi.org/10.7326/0003-4819-138-12-200306170-00008
Abstract
There is no consensus on the effectiveness of inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease (COPD). To evaluate the long-term effects of inhaled corticosteroids on the rate of FEV1 decline in patients with COPD. MEDLINE, EMBASE, CISCOM, and AMED databases and the Cochrane Library (1966 to December 2002), reference lists from identified articles, and consultation with experts. Searches were not limited to the English language. Randomized, placebo-controlled trials that examined the rate of FEV1 decline as a primary outcome in patients with COPD. Two reviewers independently extracted the data by using predetermined criteria. For the six studies that met the inclusion criteria, the summary estimate for the difference in FEV1 decline between the placebo and treatment groups was 5.0 3.2 mL/y (95% CI, 11.2 to 1.2 mL/y; P = 0.11). The use of inhaled corticosteroids was not associated with the rate of FEV1 decline in 3571 patients followed for 24 to 54 months.Keywords
This publication has 6 references indexed in Scilit:
- Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ, 2000
- The Economic Burden of COPDChest, 2000
- A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary diseaseClinical and Experimental Allergy, 1999
- Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysisThorax, 1999
- Effects of Long-term Treatment With Corticosteroids in COPDChest, 1996
- Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trialsJAMA, 1995